Zoetis Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zoetis Inc. on August 14, 2014. The filing discloses a significant change in executive leadership regarding the appointment of a new Chief Financial Officer.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change is the appointment of Paul S. Herendeen as Executive Vice President and Chief Financial Officer, effective September 2, 2014. Concurrently, Glenn David will step down as Acting Chief Financial Officer to continue serving as Senior Vice President of Finance Operations.
Management Commentary and Compensation Details
Mr. Herendeen's employment offer letter, dated July 31, 2014, outlines the following compensation package:
- Base Salary: $630,000 annually.
- Annual Incentive Plan: Target of 70% of base salary, based on company, function, and individual performance.
- Long-Term Incentive (2015 Grant): Target award of $1,750,000.
- Sign-on Award: Grant date fair value of $875,000, split equally between Stock Options and Restricted Stock Units, vesting on the third anniversary.
- Benefits: Eligibility for the Executive Severance Plan and standard U.S. benefits programs.
Mr. Herendeen brings prior experience as CFO of Warner Chilcott PLC and MedPointe, Inc. No family relationships or undisclosed arrangements exist between Mr. Herendeen and the Company's directors or officers.
Investor Verification Checklist
- Verify the effective start date of September 2, 2014, for the new CFO.
- Confirm the vesting schedule and terms of the $875,000 sign-on award.
- Review the specific performance metrics tied to the 70% annual incentive target.
- Check for any subsequent filings regarding the transition of duties from the Acting CFO.